Modernizing Human Cancer Risk Assessment of Therapeutics.

This post was originally published on this site
Related Articles

Modernizing Human Cancer Risk Assessment of Therapeutics.

Trends Pharmacol Sci. 2017 Dec 11;:

Authors: Fielden MR, Ward LD, Minocherhomji S, Nioi P, Lebrec H, Jacobson-Kram D

Abstract
Cancer risk assessment of therapeutics is plagued by poor translatability of rodent models of carcinogenesis. In order to overcome this fundamental limitation, new approaches are needed that enable us to evaluate cancer risk directly in humans and human-based cellular models. Our enhanced understanding of the mechanisms of carcinogenesis and the influence of human genome sequence variation on cancer risk motivates us to re-evaluate how we assess the carcinogenic risk of therapeutics. This review will highlight new opportunities for applying this knowledge to the development of a battery of human-based in vitro models and biomarkers for assessing cancer risk of novel therapeutics.

PMID: 29242029 [PubMed – as supplied by publisher]

Leave a comment

Your email address will not be published.


*